about
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansTransport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2Effects of 1alpha,25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivoPKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist.An integrated approach to model hepatic drug clearance.Formed and preformed metabolites: facts and comparisons.Safety testing of metabolites: Expectations and outcomes.Interplay of transporters and enzymes in drug and metabolite processing.Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.Dealing with the complex drug-drug interactions: towards mechanistic models.Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first-pass removal in rats.Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters.Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo.Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1α,25-Dihydroxyvitamin D3 in Mice.The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein.Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment.PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation.Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer.1α,25-dihydroxyvitamin D3 on intestinal transporter function: studies with the rat everted intestinal sac.The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices.1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo.Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model.Retention of transporter activities in cryopreserved, isolated rat hepatocytes.Moment analysis of metabolic heterogeneity: conjugation of benzoate with glycine in rat liver studied by multiple indicator dilution technique.A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition.Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver.Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation.Alterations in Gene Expression in Vitamin D-Deficiency: Down-Regulation of Liver Cyp7a1 and Renal Oat3 in Mice.Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury.Highlighting Vitamin D Receptor-Targeted Activities of 1α,25-Dihydroxyvitamin D3 in Mice via Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling.Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease.Commentary on "The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio".Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen.Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver.Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption.
P50
Q27022933-537340C8-C5D3-4D25-9EA0-5A9A01E8E339Q28575088-ABAFB00A-7B92-4969-9E0B-EB1FD16070D6Q28579997-C41A782A-6EF8-4CB0-AA47-EB4DD71E28FEQ35865449-1BC73E78-63D7-4137-A078-7A71E27C3BBFQ36365166-E899866B-2AD4-48C1-B878-7FC4B41EAED2Q36522333-95AF0FFC-13B6-4CF4-9C4D-483A155E4D9FQ37277366-3270B68D-59A8-46C7-A233-69D63C2C8BD5Q37300567-4A4A296E-BDDD-4BB3-8D96-B33C038D7D97Q37627862-1CEDC4D8-FDAE-418E-9524-58F28D4F9B4AQ37820451-3622D5A5-FAFD-439B-BCA3-2E7EDFF57C50Q37978192-3DC11C3D-2A5E-4B68-A358-849371E618D5Q38302225-E736BB7A-55B9-40A0-A8AE-55C717AC97BCQ39124610-D1CDE419-DE12-42C7-93B4-A527AA652E24Q39656279-7B2FC3CE-292D-4955-A5E0-6DBA503CF7AFQ39835734-97E76D82-DA24-4FD5-A839-85C2A0660D06Q40289733-D7297095-5186-4DF6-91F5-61C0C7F440FAQ40299746-7F5A5C4C-0FFC-4F10-9852-E7F9EA3129CAQ40998351-28032B7A-7D24-4626-81D4-E1CC386E1373Q41371870-A08544C6-3DC0-4C36-A31E-C7C622BEACC1Q41481541-E66C583D-8318-44AE-BBC8-59B31B182F63Q42453141-C855F730-D627-457A-9DCB-4D63D126728AQ42749433-7840D734-D5CA-4C1E-9098-62F6E76972D2Q42871300-12F149E8-4666-4DF7-BAE6-D5B19E1EC9A6Q43276744-6160F06F-AA64-4002-AD97-B02E97B34F39Q44249112-CA8C33D6-9845-4BAC-BC00-DE3AC90602C9Q44365482-E5C21BD8-5B94-4CC8-98B6-E3FFBE0ADE88Q44370443-BF00E413-6634-42C3-AC0A-7FFDB0E6C409Q45124325-90C29BA6-8722-4B7A-8837-8F4389368299Q45948489-26CDCE57-4458-417B-9006-D394E4595B38Q46933236-952D98AA-ABC2-4427-85C3-E76A60C24964Q47290783-E44544DD-B49A-425F-AB54-FE0586697573Q47340068-2F68C0DF-5871-437D-A565-A7903FFB3F60Q47587069-8227DF41-1B40-43BC-973A-826BEB825B12Q48453320-61D07E49-7C1B-4025-AFD7-54FCB60596D3Q48778991-E418B056-5A2F-4F4C-82A1-CE1E70E845BDQ50036214-896202E0-9B8D-425B-B3CF-298B866ADF1EQ50061323-F5AC1C65-2770-4719-86AE-3A68C1A1A3FCQ50139624-8CD67CD7-77F4-43DC-8341-553F8B06FAC0Q50761978-A820DD81-A643-4EFE-A575-34E19AB2F0EDQ52020293-7613E41D-C0FD-421C-9A05-AE1DCC8CB677
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
K S Pang
@en
K S Pang
@nl
type
label
K S Pang
@en
K S Pang
@nl
prefLabel
K S Pang
@en
K S Pang
@nl
P108
P106
P31
P496
0000-0002-0683-2129